London, United Kingdom

Kerry Anne Chester

This inventor holds 1 USPTO granted patent. Top assignee: Cancer Research Campaign Technology Limited. Active years: 1999.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Kerry Anne Chester. Retrieved from https://idiyas.com/inventor/kerry-anne-chester

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

Average Co-Inventor Count = 3.0

ph-index = 1

Forward Citations = 33(Granted Patents)


Company Filing History:


Years Active: 1999

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Kerry Anne Chester: Innovator in Cancer Research

Introduction

Kerry Anne Chester is a prominent inventor based in London, GB. She has made significant contributions to the field of cancer research, particularly through her innovative work on antibodies.

Latest Patents

Kerry Anne Chester holds a patent for an antibody against carcinoembryonic antigen (CEA). This invention is crucial in the ongoing battle against cancer, providing new avenues for diagnosis and treatment.

Career Highlights

Chester is associated with Cancer Research Campaign Technology Limited, where she applies her expertise to advance cancer research. Her work has been instrumental in developing new therapeutic strategies.

Collaborations

Throughout her career, Kerry has collaborated with notable colleagues, including Robert E. Hawkins and Richard Henry Begent. These partnerships have enhanced her research and contributed to the success of her projects.

Conclusion

Kerry Anne Chester's innovative work in cancer research exemplifies her dedication to improving patient outcomes. Her contributions, particularly in developing antibodies, highlight the importance of innovation in the medical field.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…